Subcutaneous tuberculosis formation during FOLFIRI and bevacizumab treatment: a case report

Int J Colorectal Dis. 2016 Apr;31(4):943-4. doi: 10.1007/s00384-015-2368-6. Epub 2015 Aug 23.

Authors

Xiao-Wei Zheng¹, Li-Li Ren², Yi-Wen Zhang¹, Wen-Juan Yin³, Gang Tao⁴, Wen-Xiu Xin¹, Zhong-Jian Chen¹, Ping Huang⁵

Affiliations

¹ Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
² Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
³ Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
⁴ Emergency Department, Hanggang Hospital, Hangzhou, 310022, Zhejiang, China.
⁵ Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China. 37751812@qq.com.

PMID: 26298180
DOI: 10.1007/s00384-015-2368-6

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Bevacizumab / adverse effects*
Camptothecin / adverse effects
Camptothecin / analogs & derivatives*
Female
Fluorouracil / adverse effects
Humans
Leucovorin / adverse effects
Subcutaneous Tissue / pathology*
Tuberculosis / chemically induced*

Substances

Bevacizumab
Leucovorin
Fluorouracil
Camptothecin

Supplementary concepts

IFL protocol